King Pharmaceuticals, Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2008 (May 15, 2008)
King Pharmaceuticals, Inc.
 
(Exact name of registrant as specified in charter)
         
Tennessee   001-15875   54-1684963
 
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
     
501 Fifth Street, Bristol, Tennessee   37620
 
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (423) 989-8000
N/A
 
(Former name or former address, if changed since last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On May 15, 2008, the Compensation and Human Resources Committee of the Board of Directors of King Pharmaceuticals, Inc. (“King”) approved a Form of Restricted Unit Certificate and Restricted Unit Grant Agreement, attached hereto as Exhibit 10.1, to be used in connection with King’s Incentive Plan. This form of agreement is being used in connection with the annual grants made to the independent directors of King pursuant to King’s Incentive Plan on May 15, 2008.
Item 9.01   Financial Statements and Exhibits.
     (d) Exhibits
         
       
 
  10.1    
Form of Restricted Unit Certificate and Restricted Unit Grant Agreement

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: May 21, 2008  KING PHARMACEUTICALS, INC.
 		  
  By:   /s/ Joseph Squicciarino    
    Joseph Squicciarino   
    Chief Financial Officer   

 

 

         
EXHIBIT INDEX
         
Exhibit No.   Description
       
 
  10.1    
Form of Restricted Unit Certificate and Restricted Unit Grant Agreement